SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!
Luny
Lv1
60 积分
2024-03-18 加入
最近求助
最近应助
互助留言
Sacituzumab govitecan-hziy for triple-negative breast cancer
5天前
已完结
Long-term Quality of Life and Functional Outcome of Patients With Rectal Cancer Following a Watch-and-Wait Approach
5天前
已关闭
22MO Efficacy and safety of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer (mTNBC) by baseline HER2 expression level: Subgroup analysis from a phase IIb trial
5天前
已完结
Efficacy of sacituzumab govitecan based regimen in triple-negative breast cancer: A systematic review
5天前
已完结
ISOPP 2023 – Abstract Book
5天前
已完结
393P Real-world (RW) use patterns, effectiveness, and tolerability of sacituzumab govitecan (SG) for second-line (2L) and later treatment of metastatic triple-negative breast cancer (mTNBC)
11天前
已关闭
Sacituzumab Govitecan as a Second-Line Treatment in Relapsed/Refractory Metastatic Triple-Negative Breast Cancer Patients: A Systematic Review and Meta-analysis
13天前
已完结
戈沙妥珠单抗治疗晚期三阴性乳腺癌1例
15天前
已完结
Discovery of New Targets to Control Metastasis in Pancreatic Cancer by Single-cell Transcriptomics Analysis of Circulating Tumor Cells
27天前
已关闭
Sacituzumab Govitecan as a Second-Line Treatment in Relapsed/Refractory Metastatic Triple-Negative Breast Cancer Patients: A Systematic Review and Meta-analysis
1个月前
已完结
没有进行任何应助
识别错误【积分已退回】
5天前
自动识别的标题错误,不好意思!
5天前
未找到【积分已退回】
27天前
不是需要的文章
27天前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论